Maxine Sun1, Lorenzo Marconi2, Tim Eisen3, Bernard Escudier4, Rachel H Giles5, Naomi B Haas6, Lauren C Harshman1, David I Quinn7, James Larkin8, Sumanta K Pal9, Thomas Powles10, Christopher W Ryan11, Cora N Sternberg12, Robert Uzzo13, Toni K Choueiri14, Axel Bex15. 1. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2. Department of Urology, Coimbra University Hospital, Coimbra, Portugal. 3. Department of Oncology, Addenbrooke's Hospital, Cambridge Biomedical Research Centre, UK. 4. Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France. 5. Patient Advocate, International Kidney Cancer Coalition, Duivendrecht, The Netherlands; Department Nephrology and Hypertension, Regenerative Medicine Center Utrecht, University Medical Center Utrecht, University of Utrecht, The Netherlands. 6. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. 7. Section of Genitourinary Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA. 8. Royal Marsden NHS Trust Foundation Trust, London, UK. 9. Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 10. The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. 11. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 12. Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. 13. Department of Surgery, Fox Chase Cancer Center - Temple University Health System, Philadelphia, PA, USA. 14. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Toni_Choueiri@dfci.harvard.edu. 15. Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@nki.nl.
Abstract
CONTEXT: Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC). OBJECTIVE: To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. EVIDENCE ACQUISITION: A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed. We identified reports and reviewed them according to the Consolidated Standards of Reporting Trials and Standards for the Reporting of Diagnostic Accuracy Studies criteria. Of eight full-text articles that were eligible for inclusion, five studies (two of five were updated analyses) were retained in the final synthesis. Study characteristics were abstracted and the number needed to treat (NNT) per trial was estimated. EVIDENCE SYNTHESIS: The three randomized controlled phase III trials included the following comparisons: sunitinib versus placebo or sorafenib versus placebo (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma [ASSURE] study, n=1943), sunitinib versus placebo (S-TRAC, n=615), and pazopanib versus placebo (Pazopanib As Adjuvant Therapy in Localized/Locally Advanced RCC After Nephrectomy study, n=1135). The NNT ranged from 10 (S-TRAC) to 137 (ASSURE study). The pooled analysis showed that VEGFR-targeted therapy was not statistically significantly associated with improved DFS (hazard ratio [HRrandom]: 0.92, 95% confidence interval [CI]: 0.82-1.03, p=0.16) or OS (HRrandom: 0.98, 95% CI: 0.84-1.15, p=0.84) compared with the control group. The adjuvant therapy group experienced significantly higher odds of grade 3-4 AEs (ORrandom: 5.89, 95% CI: 4.85-7.15, p<0.001). In exploratory analyses focusing on patients who started on the full-dose regimen, DFS was improved in patients who received adjuvant therapy (HRrandom: 0.83, 95% CI: 0.73-0.95, p=0.005). CONCLUSIONS: This pooled analysis of reported randomized trials did not reveal a statistically significant effect between adjuvant VEGFR-targeted therapy and improved DFS or OS in patients with intermediate/high-risk local or regional fully resected RCC. Improvement in DFS may be more likely with the use of full-dose regimens, pending further results. However, adjuvant treatment was associated with high-grade AEs. PATIENT SUMMARY: Vascular endothelial growth factor receptor-targeted therapy after nephrectomy for localized kidney cancer is not associated with consistent improvements in delaying cancer recurrence or prolonging life and comes at the expense of potentially significant side effects.
CONTEXT: Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC). OBJECTIVE: To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. EVIDENCE ACQUISITION: A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed. We identified reports and reviewed them according to the Consolidated Standards of Reporting Trials and Standards for the Reporting of Diagnostic Accuracy Studies criteria. Of eight full-text articles that were eligible for inclusion, five studies (two of five were updated analyses) were retained in the final synthesis. Study characteristics were abstracted and the number needed to treat (NNT) per trial was estimated. EVIDENCE SYNTHESIS: The three randomized controlled phase III trials included the following comparisons: sunitinib versus placebo or sorafenib versus placebo (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma [ASSURE] study, n=1943), sunitinib versus placebo (S-TRAC, n=615), and pazopanib versus placebo (Pazopanib As Adjuvant Therapy in Localized/Locally Advanced RCC After Nephrectomy study, n=1135). The NNT ranged from 10 (S-TRAC) to 137 (ASSURE study). The pooled analysis showed that VEGFR-targeted therapy was not statistically significantly associated with improved DFS (hazard ratio [HRrandom]: 0.92, 95% confidence interval [CI]: 0.82-1.03, p=0.16) or OS (HRrandom: 0.98, 95% CI: 0.84-1.15, p=0.84) compared with the control group. The adjuvant therapy group experienced significantly higher odds of grade 3-4 AEs (ORrandom: 5.89, 95% CI: 4.85-7.15, p<0.001). In exploratory analyses focusing on patients who started on the full-dose regimen, DFS was improved in patients who received adjuvant therapy (HRrandom: 0.83, 95% CI: 0.73-0.95, p=0.005). CONCLUSIONS: This pooled analysis of reported randomized trials did not reveal a statistically significant effect between adjuvant VEGFR-targeted therapy and improved DFS or OS in patients with intermediate/high-risk local or regional fully resected RCC. Improvement in DFS may be more likely with the use of full-dose regimens, pending further results. However, adjuvant treatment was associated with high-grade AEs. PATIENT SUMMARY:Vascular endothelial growth factor receptor-targeted therapy after nephrectomy for localized kidney cancer is not associated with consistent improvements in delaying cancer recurrence or prolonging life and comes at the expense of potentially significant side effects.
Authors: Axel Bex; Laurence Albiges; Börje Ljungberg; Karim Bensalah; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Michael Staehler; Alessandro Volpe; Thomas Powles Journal: Eur Urol Date: 2016-12-13 Impact factor: 20.096
Authors: Lauren C Harshman; Wanling Xie; Raphael B Moreira; Dominick Bossé; Gustavo J Ruiz Ares; Christopher J Sweeney; Toni K Choueiri Journal: Cancer Date: 2017-12-19 Impact factor: 6.860
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola Journal: Lancet Date: 2016-03-09 Impact factor: 79.321
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Tim Eisen; Eleni Frangou; Bhavna Oza; Alastair W S Ritchie; Benjamin Smith; Rick Kaplan; Ian D Davis; Martin R Stockler; Laurence Albiges; Bernard Escudier; James Larkin; Axel Bex; Steven Joniau; Barry Hancock; Gregers G Hermann; Joaquim Bellmunt; Elizabeth Hodgkinson; Grant D Stewart; Jim Barber; Janet Brown; Rhona McMenemin; Paul Nathan; Lisa M Pickering; Mahesh K B Parmar; Angela Meade Journal: J Clin Oncol Date: 2020-10-14 Impact factor: 44.544
Authors: Anup Patel; Alain Ravaud; Robert J Motzer; Allan J Pantuck; Michael Staehler; Bernard Escudier; Jean-François Martini; Mariajose Lechuga; Xun Lin; Daniel J George Journal: Clin Cancer Res Date: 2020-06-16 Impact factor: 12.531